ID   NAP1_YEAST              Reviewed;         417 AA.
AC   P25293; D6VXA9; P87196;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 2.
DT   28-JAN-2026, entry version 221.
DE   RecName: Full=Nucleosome assembly protein {ECO:0000303|PubMed:2016313};
DE   AltName: Full=Histone H2A-H2B chaperone NAP1 {ECO:0000305};
DE   AltName: Full=Protein chaperone NAP1 {ECO:0000305};
DE   AltName: Full=Ribosome assembly chaperone NAP1 {ECO:0000305};
GN   Name=NAP1 {ECO:0000303|PubMed:2016313};
GN   OrderedLocusNames=YKR048C {ECO:0000312|SGD:S000001756};
OS   Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Saccharomycotina; Saccharomycetes;
OC   Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX   NCBI_TaxID=559292;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND FUNCTION.
RX   PubMed=2016313; DOI=10.1016/s0021-9258(20)89604-5;
RA   Ishimi Y., Kikuchi A.;
RT   "Identification and molecular cloning of yeast homolog of nucleosome
RT   assembly protein I which facilitates nucleosome assembly in vitro.";
RL   J. Biol. Chem. 266:7025-7029(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=8196765; DOI=10.1038/369371a0;
RA   Dujon B., Alexandraki D., Andre B., Ansorge W., Baladron V.,
RA   Ballesta J.P.G., Banrevi A., Bolle P.-A., Bolotin-Fukuhara M., Bossier P.,
RA   Bou G., Boyer J., Buitrago M.J., Cheret G., Colleaux L.,
RA   Daignan-Fornier B., del Rey F., Dion C., Domdey H., Duesterhoeft A.,
RA   Duesterhus S., Entian K.-D., Erfle H., Esteban P.F., Feldmann H.,
RA   Fernandes L., Fobo G.M., Fritz C., Fukuhara H., Gabel C., Gaillon L.,
RA   Garcia-Cantalejo J.M., Garcia-Ramirez J.J., Gent M.E., Ghazvini M.,
RA   Goffeau A., Gonzalez A., Grothues D., Guerreiro P., Hegemann J.H.,
RA   Hewitt N., Hilger F., Hollenberg C.P., Horaitis O., Indge K.J.,
RA   Jacquier A., James C.M., Jauniaux J.-C., Jimenez A., Keuchel H.,
RA   Kirchrath L., Kleine K., Koetter P., Legrain P., Liebl S., Louis E.J.,
RA   Maia e Silva A., Marck C., Monnier A.-L., Moestl D., Mueller S.,
RA   Obermaier B., Oliver S.G., Pallier C., Pascolo S., Pfeiffer F.,
RA   Philippsen P., Planta R.J., Pohl F.M., Pohl T.M., Poehlmann R.,
RA   Portetelle D., Purnelle B., Puzos V., Ramezani Rad M., Rasmussen S.W.,
RA   Remacha M.A., Revuelta J.L., Richard G.-F., Rieger M.,
RA   Rodrigues-Pousada C., Rose M., Rupp T., Santos M.A., Schwager C.,
RA   Sensen C., Skala J., Soares H., Sor F., Stegemann J., Tettelin H.,
RA   Thierry A., Tzermia M., Urrestarazu L.A., van Dyck L.,
RA   van Vliet-Reedijk J.C., Valens M., Vandenbol M., Vilela C., Vissers S.,
RA   von Wettstein D., Voss H., Wiemann S., Xu G., Zimmermann J., Haasemann M.,
RA   Becker I., Mewes H.-W.;
RT   "Complete DNA sequence of yeast chromosome XI.";
RL   Nature 369:371-378(1994).
RN   [3]
RP   GENOME REANNOTATION.
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=24374639; DOI=10.1534/g3.113.008995;
RA   Engel S.R., Dietrich F.S., Fisk D.G., Binkley G., Balakrishnan R.,
RA   Costanzo M.C., Dwight S.S., Hitz B.C., Karra K., Nash R.S., Weng S.,
RA   Wong E.D., Lloyd P., Skrzypek M.S., Miyasato S.R., Simison M., Cherry J.M.;
RT   "The reference genome sequence of Saccharomyces cerevisiae: Then and now.";
RL   G3 (Bethesda) 4:389-398(2014).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=17322287; DOI=10.1101/gr.6037607;
RA   Hu Y., Rolfs A., Bhullar B., Murthy T.V.S., Zhu C., Berger M.F.,
RA   Camargo A.A., Kelley F., McCarron S., Jepson D., Richardson A., Raphael J.,
RA   Moreira D., Taycher E., Zuo D., Mohr S., Kane M.F., Williamson J.,
RA   Simpson A.J.G., Bulyk M.L., Harlow E., Marsischky G., Kolodner R.D.,
RA   LaBaer J.;
RT   "Approaching a complete repository of sequence-verified protein-encoding
RT   clones for Saccharomyces cerevisiae.";
RL   Genome Res. 17:536-543(2007).
RN   [5]
RP   PROTEIN SEQUENCE OF 251-256, FUNCTION, INTERACTION WITH CLB2, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=7622566; DOI=10.1083/jcb.130.3.661;
RA   Kellogg D.R., Kikuchi A., Fujii-Nakata T., Turck C.W., Murray A.W.;
RT   "Members of the NAP/SET family of proteins interact specifically with B-
RT   type cyclins.";
RL   J. Cell Biol. 130:661-673(1995).
RN   [6]
RP   FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE
RP   GIN4 COMPLEX.
RX   PubMed=12058072; DOI=10.1091/mbc.01-10-0500;
RA   Mortensen E.M., McDonald H., Yates J. III, Kellogg D.R.;
RT   "Cell cycle-dependent assembly of a Gin4-septin complex.";
RL   Mol. Biol. Cell 13:2091-2105(2002).
RN   [7]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RX   PubMed=14562095; DOI=10.1038/nature02026;
RA   Huh W.-K., Falvo J.V., Gerke L.C., Carroll A.S., Howson R.W.,
RA   Weissman J.S., O'Shea E.K.;
RT   "Global analysis of protein localization in budding yeast.";
RL   Nature 425:686-691(2003).
RN   [8]
RP   LEVEL OF PROTEIN EXPRESSION [LARGE SCALE ANALYSIS].
RX   PubMed=14562106; DOI=10.1038/nature02046;
RA   Ghaemmaghami S., Huh W.-K., Bower K., Howson R.W., Belle A., Dephoure N.,
RA   O'Shea E.K., Weissman J.S.;
RT   "Global analysis of protein expression in yeast.";
RL   Nature 425:737-741(2003).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   STRAIN=YAL6B;
RX   PubMed=15665377; DOI=10.1074/mcp.m400219-mcp200;
RA   Gruhler A., Olsen J.V., Mohammed S., Mortensen P., Faergeman N.J., Mann M.,
RA   Jensen O.N.;
RT   "Quantitative phosphoproteomics applied to the yeast pheromone signaling
RT   pathway.";
RL   Mol. Cell. Proteomics 4:310-327(2005).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-20; THR-24; SER-27; SER-76
RP   AND SER-177, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   STRAIN=ADR376;
RX   PubMed=17330950; DOI=10.1021/pr060559j;
RA   Li X., Gerber S.A., Rudner A.D., Beausoleil S.A., Haas W., Villen J.,
RA   Elias J.E., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of alpha-factor-arrested
RT   Saccharomyces cerevisiae.";
RL   J. Proteome Res. 6:1190-1197(2007).
RN   [11]
RP   FUNCTION, INTERACTION WITH RPL18A OR RPL18B; CKA2; CKI1; TEF1 OR TEF2;
RP   FOL1; HSC82; HTA2; HTB2; HTZ1; KAP114; KCC4; NIS1; SSA1; SSA2; SSB1; SSC1;
RP   SHM1; SIP5; TCO89 AND NBA1, SUBCELLULAR LOCATION, DISRUPTION PHENOTYPE,
RP   PHOSPHORYLATION AT SER-82; SER-98; SER-104 AND SER-140, PHOSPHORYLATION AT
RP   SER-159; SER-177 AND SER-397 BY CK2, MUTAGENESIS OF LEU-99; SER-159;
RP   SER-177 AND SER-397, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18086883; DOI=10.1128/mcb.01035-07;
RA   Calvert M.E.K., Keck K.M., Ptak C., Shabanowitz J., Hunt D.F.,
RA   Pemberton L.F.;
RT   "Phosphorylation by casein kinase 2 regulates Nap1 localization and
RT   function.";
RL   Mol. Cell. Biol. 28:1313-1325(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-20; THR-24; SER-27; SER-76;
RP   SER-140 AND SER-177, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=18407956; DOI=10.1074/mcp.m700468-mcp200;
RA   Albuquerque C.P., Smolka M.B., Payne S.H., Bafna V., Eng J., Zhou H.;
RT   "A multidimensional chromatography technology for in-depth phosphoproteome
RT   analysis.";
RL   Mol. Cell. Proteomics 7:1389-1396(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-20; THR-24; SER-27; THR-53;
RP   SER-69; SER-76; SER-82 AND SER-177, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19779198; DOI=10.1126/science.1172867;
RA   Holt L.J., Tuch B.B., Villen J., Johnson A.D., Gygi S.P., Morgan D.O.;
RT   "Global analysis of Cdk1 substrate phosphorylation sites provides insights
RT   into evolution.";
RL   Science 325:1682-1686(2009).
RN   [14]
RP   UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-50, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22106047; DOI=10.1002/pmic.201100166;
RA   Starita L.M., Lo R.S., Eng J.K., von Haller P.D., Fields S.;
RT   "Sites of ubiquitin attachment in Saccharomyces cerevisiae.";
RL   Proteomics 12:236-240(2012).
RN   [15]
RP   INTERACTION WITH HISTONE H3/H4 HETERODIMERS.
RX   PubMed=27036862; DOI=10.1093/nar/gkw209;
RA   Hammond C.M., Sundaramoorthy R., Larance M., Lamond A., Stevens M.A.,
RA   El-Mkami H., Norman D.G., Owen-Hughes T.;
RT   "The histone chaperone Vps75 forms multiple oligomeric assemblies capable
RT   of mediating exchange between histone H3-H4 tetramers and Asf1-H3-H4
RT   complexes.";
RL   Nucleic Acids Res. 44:6157-6172(2016).
RN   [16]
RP   FUNCTION, INTERACTION WITH RPS6A AND RPS6B, AND DISRUPTION PHENOTYPE.
RX   PubMed=31062022; DOI=10.1093/nar/gkz317;
RA   Roessler I., Embacher J., Pillet B., Murat G., Liesinger L., Hafner J.,
RA   Unterluggauer J.J., Birner-Gruenberger R., Kressler D., Pertschy B.;
RT   "Tsr4 and Nap1, two novel members of the ribosomal protein chaperOME.";
RL   Nucleic Acids Res. 47:6984-7002(2019).
RN   [17] {ECO:0007744|PDB:2AYU}
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS), AND SUBUNIT.
RX   PubMed=16432217; DOI=10.1073/pnas.0508002103;
RA   Park Y.-J., Luger K.;
RT   "The structure of nucleosome assembly protein 1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:1248-1253(2006).
RN   [18] {ECO:0007744|PDB:2Z2R}
RP   X-RAY CRYSTALLOGRAPHY (3.20 ANGSTROMS) OF 74-365, SUBUNIT, INTERACTION WITH
RP   H2A AND H2B, AND MUTAGENESIS OF 290-ARG--LYS-305; ARG-290 AND LYS-305.
RX   PubMed=18068721; DOI=10.1016/j.jmb.2007.11.031;
RA   Park Y.J., McBryant S.J., Luger K.;
RT   "A beta-hairpin comprising the nuclear localization sequence sustains the
RT   self-associated states of nucleosome assembly protein 1.";
RL   J. Mol. Biol. 375:1076-1085(2008).
RN   [19] {ECO:0007744|PDB:5G2E}
RP   X-RAY CRYSTALLOGRAPHY (6.70 ANGSTROMS) OF 74-372 IN COMPLEX WITH XENOPUS
RP   H2A AND H2B, FUNCTION, SUBUNIT, AND DISRUPTION PHENOTYPE.
RX   PubMed=27225933; DOI=10.15252/embj.201694105;
RA   Aguilar-Gurrieri C., Larabi A., Vinayachandran V., Patel N.A., Yen K.,
RA   Reja R., Ebong I.O., Schoehn G., Robinson C.V., Pugh B.F., Panne D.;
RT   "Structural evidence for Nap1-dependent H2A-H2B deposition and nucleosome
RT   assembly.";
RL   EMBO J. 35:1465-1482(2016).
RN   [20] {ECO:0007744|PDB:9B23, ECO:0007744|PDB:9B31, ECO:0007744|PDB:9B3F, ECO:0007744|PDB:9B3I}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.88 ANGSTROMS) OF 3-417 IN COMPLEX WITH
RP   HTA2; HTB2; KAP114 AND GSP1, SUBUNIT, INTERACTION WITH KAP114; GSP1 AND
RP   HISTONE H2A-H2B DIMERS, AND MUTAGENESIS OF 288-GLU--GLN-292.
RX   PubMed=39601790; DOI=10.1083/jcb.202408193;
RA   Fung H.Y.J., Jiou J., Niesman A.B., Bernardes N.E., Chook Y.M.;
RT   "Nap1 and Kap114 co-chaperone H2A-H2B and facilitate targeted histone
RT   release in the nucleus.";
RL   J. Cell Biol. 224:e202408193-e202408193(2025).
CC   -!- FUNCTION: Histone H2A-H2B chaperone that together with karyopherin
CC       KAP114 co-chaperones histone H2A-H2B dimers into the nucleus;
CC       subsequent binding of RAN(GTP) GSP1 to this complex promotes specific
CC       and accurate deposition of H2A-H2B into nucleosomes (PubMed:18086883,
CC       PubMed:2016313, PubMed:27225933). Also acts as an assembly chaperone
CC       for the small ribosomal subunit protein eS6 (RPS6A and RPS6B), thereby
CC       functioning in 40S ribosomal subunit biogenesis (PubMed:31062022). May
CC       also chaperone the large ribosomal subunit proteins eL39 and eL42
CC       (PubMed:31062022). Plays a role in the regulation of the cell cycle;
CC       regulates the localization and function of septins during mitosis, and
CC       the function of B-type cyclins (PubMed:12058072, PubMed:18086883,
CC       PubMed:7622566). {ECO:0000269|PubMed:12058072,
CC       ECO:0000269|PubMed:18086883, ECO:0000269|PubMed:2016313,
CC       ECO:0000269|PubMed:27225933, ECO:0000269|PubMed:31062022,
CC       ECO:0000269|PubMed:7622566}.
CC   -!- SUBUNIT: Homodimer (PubMed:16432217, PubMed:18068721, PubMed:27225933,
CC       PubMed:39601790). Component of the GIN4 complex composed of at least
CC       BNI5, CDC3, CDC10, CDC11, CDC12, GIN4, NAP1 and SHS1 which forms a ring
CC       at the bud neck (PubMed:12058072). Interacts with karyopherin KAP114
CC       (via C-terminus); the interaction is direct and for the nuclear import
CC       of histone H2A-H2B dimers and their assembly into nucleosomes
CC       (PubMed:39601790). Interacts with RAN(GTP) GSP1; for assembly of
CC       histone H2A-H2B dimers into nucleosomes (PubMed:39601790). Interacts
CC       with histones H2A and H2B; the interaction is direct and NAP1 dimers
CC       bind H2A-H2B dimers, and these complexes assemble into higher order
CC       oligomers (PubMed:16432217, PubMed:18068721, PubMed:18086883,
CC       PubMed:27225933, PubMed:39601790). Interacts (via C-terminus) with
CC       small ribosomal subunit protein eS6 (RPS6A and RPS6B); the interaction
CC       is direct and required for proper ribosome assembly (PubMed:31062022).
CC       Interacts with the B-type cyclin CLB2 (PubMed:7622566). Interacts with
CC       60S ribosomal protein L18 (RPL18A or RPL18B), CKA2, CKI1, eukaryotic
CC       elongation factor 1 complex eEF1A (TEF1 or TEF2), FOL1, HSC82, HTZ1,
CC       KAP114, KCC4, NIS1, SSA1, SSA2, SSB1, SSC1, SHM1, SIP5 and TCO89
CC       (PubMed:18086883). Interacts with NBA1 (PubMed:18086883). Interacts
CC       with histone H3/H4 heterodimers (PubMed:27036862).
CC       {ECO:0000269|PubMed:12058072, ECO:0000269|PubMed:16432217,
CC       ECO:0000269|PubMed:18068721, ECO:0000269|PubMed:18086883,
CC       ECO:0000269|PubMed:27036862, ECO:0000269|PubMed:27225933,
CC       ECO:0000269|PubMed:31062022, ECO:0000269|PubMed:39601790,
CC       ECO:0000269|PubMed:7622566}.
CC   -!- INTERACTION:
CC       P25293; Q99299: AIM44; NbExp=5; IntAct=EBI-11850, EBI-29423;
CC       P25293; Q12114: CHS5; NbExp=2; IntAct=EBI-11850, EBI-4640;
CC       P25293; P20485: CKI1; NbExp=5; IntAct=EBI-11850, EBI-9699;
CC       P25293; Q06440: CRN1; NbExp=3; IntAct=EBI-11850, EBI-4950;
CC       P25293; P53168: DUO1; NbExp=2; IntAct=EBI-11850, EBI-23800;
CC       P25293; Q12263: GIN4; NbExp=19; IntAct=EBI-11850, EBI-7595;
CC       P25293; Q04458: HFD1; NbExp=2; IntAct=EBI-11850, EBI-27205;
CC       P25293; P61830: HHT2; NbExp=7; IntAct=EBI-11850, EBI-8098;
CC       P25293; P04911: HTA1; NbExp=6; IntAct=EBI-11850, EBI-8072;
CC       P25293; P04912: HTA2; NbExp=35; IntAct=EBI-11850, EBI-8076;
CC       P25293; P02293: HTB1; NbExp=18; IntAct=EBI-11850, EBI-8088;
CC       P25293; P02294: HTB2; NbExp=25; IntAct=EBI-11850, EBI-8094;
CC       P25293; Q12692: HTZ1; NbExp=23; IntAct=EBI-11850, EBI-8080;
CC       P25293; P53067: KAP114; NbExp=5; IntAct=EBI-11850, EBI-9174;
CC       P25293; P25389: KCC4; NbExp=11; IntAct=EBI-11850, EBI-9607;
CC       P25293; P25293: NAP1; NbExp=4; IntAct=EBI-11850, EBI-11850;
CC       P25293; P53939: NIS1; NbExp=9; IntAct=EBI-11850, EBI-28760;
CC       P25293; P53261: NOP7; NbExp=2; IntAct=EBI-11850, EBI-13145;
CC       P25293; P32263: PRO3; NbExp=3; IntAct=EBI-11850, EBI-13885;
CC       P25293; P41940: PSA1; NbExp=3; IntAct=EBI-11850, EBI-11191;
CC       P25293; P38344: REI1; NbExp=12; IntAct=EBI-11850, EBI-21136;
CC       P25293; P38615: RIM11; NbExp=14; IntAct=EBI-11850, EBI-10642;
CC       P25293; P53030: RPL1B; NbExp=2; IntAct=EBI-11850, EBI-14442;
CC       P25293; P02365: RPS6B; NbExp=2; IntAct=EBI-11850, EBI-16154;
CC       P25293; Q07794: RTT109; NbExp=2; IntAct=EBI-11850, EBI-2887026;
CC       P25293; P53313: SDA1; NbExp=10; IntAct=EBI-11850, EBI-23572;
CC       P25293; P32558: SPT16; NbExp=5; IntAct=EBI-11850, EBI-4334;
CC       P25293; P40150: SSB2; NbExp=15; IntAct=EBI-11850, EBI-8632;
CC       P25293; Q08921: TCO89; NbExp=3; IntAct=EBI-11850, EBI-37395;
CC       P25293; Q06685: VIP1; NbExp=6; IntAct=EBI-11850, EBI-35034;
CC       P25293; Q12152: YPL150W; NbExp=3; IntAct=EBI-11850, EBI-37557;
CC       P25293; Q12159: YRA1; NbExp=2; IntAct=EBI-11850, EBI-29516;
CC       P25293; P40517: YRB2; NbExp=2; IntAct=EBI-11850, EBI-29534;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18086883}. Nucleus
CC       {ECO:0000269|PubMed:18086883}. Bud neck {ECO:0000269|PubMed:18086883}.
CC       Note=Phosphorylation by CK2 promotes the import into the nucleus.
CC       {ECO:0000269|PubMed:18086883}.
CC   -!- DOMAIN: The acidic domains are probably involved in the interaction
CC       with histones. {ECO:0000269|PubMed:16432217}.
CC   -!- PTM: Phosphorylation by CK2 is required for normal progression through
CC       S phase. CK2 phosphorylation is not required for correct bud formation
CC       nor histone binding. {ECO:0000269|PubMed:18086883}.
CC   -!- DISRUPTION PHENOTYPE: Leads to abnormal nucleosome assembly
CC       (PubMed:27225933). Reduces translation efficiency (PubMed:31062022).
CC       Exhibits a large proportion of multinucleate cells (PubMed:18086883).
CC       Elongated buds (PubMed:18086883). The percentage of elongated buds is
CC       significantly increased when GIN4 or CKI1 is also deleted
CC       (PubMed:18086883). Small decrease in the percentage of cells with
CC       elongated buds is observed in NAP1 and CKA2 double mutant
CC       (PubMed:18086883). NAP1 and CKI1 double mutant exhibits increased
CC       sensitivity to benomyl (PubMed:18086883). Increased resistance to
CC       benomyl in NAP1 and CKA2 double mutant (PubMed:18086883).
CC       {ECO:0000269|PubMed:18086883, ECO:0000269|PubMed:27225933,
CC       ECO:0000269|PubMed:31062022}.
CC   -!- MISCELLANEOUS: Present with 8070 molecules/cell in log phase SD medium.
CC       {ECO:0000269|PubMed:14562106}.
CC   -!- SIMILARITY: Belongs to the nucleosome assembly protein (NAP) family.
CC       {ECO:0000305}.
CC   -!- CAUTION: NAP-I was previously referred to as AP-I. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M63555; AAA34811.1; -; Genomic_DNA.
DR   EMBL; AY692777; AAT92796.1; -; Genomic_DNA.
DR   EMBL; Z28272; CAA82124.2; -; Genomic_DNA.
DR   EMBL; Z28273; CAA82125.1; -; Genomic_DNA.
DR   EMBL; BK006944; DAA09199.1; -; Genomic_DNA.
DR   PIR; S38122; S38122.
DR   RefSeq; NP_012974.1; NM_001179838.1.
DR   PDB; 2AYU; X-ray; 3.00 A; A=1-417.
DR   PDB; 2Z2R; X-ray; 3.20 A; A/B=74-365.
DR   PDB; 5G2E; X-ray; 6.70 A; A/B/E/F/I/J/M/N/Q/R/U/V=74-372.
DR   PDB; 9B23; EM; 3.20 A; D/E=74-365.
DR   PDB; 9B31; EM; 3.20 A; D/E=74-365.
DR   PDB; 9B3F; EM; 3.54 A; D/E=74-365.
DR   PDB; 9B3I; EM; 2.88 A; E/F=3-417.
DR   PDBsum; 2AYU; -.
DR   PDBsum; 2Z2R; -.
DR   PDBsum; 5G2E; -.
DR   PDBsum; 9B23; -.
DR   PDBsum; 9B31; -.
DR   PDBsum; 9B3F; -.
DR   PDBsum; 9B3I; -.
DR   AlphaFoldDB; P25293; -.
DR   SMR; P25293; -.
DR   BioGRID; 34179; 494.
DR   ComplexPortal; CPX-1712; Gin4 serine/threonine kinase complex.
DR   DIP; DIP-1380N; -.
DR   FunCoup; P25293; 2156.
DR   IntAct; P25293; 129.
DR   MINT; P25293; -.
DR   STRING; 4932.YKR048C; -.
DR   iPTMnet; P25293; -.
DR   PaxDb; 4932-YKR048C; -.
DR   PeptideAtlas; P25293; -.
DR   EnsemblFungi; YKR048C_mRNA; YKR048C; YKR048C.
DR   GeneID; 853922; -.
DR   KEGG; sce:YKR048C; -.
DR   AGR; SGD:S000001756; -.
DR   SGD; S000001756; NAP1.
DR   VEuPathDB; FungiDB:YKR048C; -.
DR   eggNOG; KOG1507; Eukaryota.
DR   HOGENOM; CLU_038841_1_0_1; -.
DR   InParanoid; P25293; -.
DR   OMA; AAECKQN; -.
DR   OrthoDB; 27325at2759; -.
DR   BioCyc; YEAST:G3O-32018-MONOMER; -.
DR   BioGRID-ORCS; 853922; 3 hits in 10 CRISPR screens.
DR   EvolutionaryTrace; P25293; -.
DR   PRO; PR:P25293; -.
DR   Proteomes; UP000002311; Chromosome XI.
DR   RNAct; P25293; protein.
DR   GO; GO:0032153; C:cell division site; IDA:SGD.
DR   GO; GO:0032174; C:cellular bud neck septin collar; IDA:SGD.
DR   GO; GO:0000785; C:chromatin; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:1990317; C:Gin4 complex; IPI:ComplexPortal.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0030332; F:cyclin binding; IPI:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0008047; F:enzyme activator activity; IDA:SGD.
DR   GO; GO:0000511; F:H2A-H2B histone complex chaperone activity; IDA:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IDA:SGD.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0140597; F:protein carrier chaperone; IDA:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; IDA:SGD.
DR   GO; GO:0007117; P:budding cell bud growth; IMP:SGD.
DR   GO; GO:0006607; P:NLS-bearing protein import into nucleus; IMP:SGD.
DR   GO; GO:0006334; P:nucleosome assembly; IDA:UniProtKB.
DR   GO; GO:0006337; P:nucleosome disassembly; IDA:SGD.
DR   GO; GO:0031116; P:positive regulation of microtubule polymerization; IMP:SGD.
DR   GO; GO:0032968; P:positive regulation of transcription elongation by RNA polymerase II; IDA:SGD.
DR   GO; GO:0098841; P:protein localization to cell division site after cytokinesis; IMP:SGD.
DR   GO; GO:0042274; P:ribosomal small subunit biogenesis; IGI:SGD.
DR   GO; GO:0000921; P:septin ring assembly; NAS:ComplexPortal.
DR   GO; GO:0000920; P:septum digestion after cytokinesis; NAS:ComplexPortal.
DR   FunFam; 3.30.1120.90:FF:000003; Nucleosome assembly protein; 1.
DR   FunFam; 1.20.5.1500:FF:000001; Nucleosome assembly protein 1-like 1; 1.
DR   Gene3D; 1.20.5.1500; -; 1.
DR   Gene3D; 3.30.1120.90; Nucleosome assembly protein; 1.
DR   InterPro; IPR037231; NAP-like_sf.
DR   InterPro; IPR002164; NAP_family.
DR   PANTHER; PTHR11875; TESTIS-SPECIFIC Y-ENCODED PROTEIN; 1.
DR   Pfam; PF00956; NAP; 1.
DR   SUPFAM; SSF143113; NAP-like; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Chaperone; Cytoplasm; Direct protein sequencing; DNA-binding;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Reference proteome;
KW   Ubl conjugation.
FT   CHAIN           1..417
FT                   /note="Nucleosome assembly protein"
FT                   /id="PRO_0000185659"
FT   DNA_BIND        330..356
FT                   /note="H-T-H motif"
FT                   /evidence="ECO:0000255"
FT   REGION          1..47
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          143..362
FT                   /note="Interaction with NBA1"
FT                   /evidence="ECO:0000269|PubMed:18086883"
FT   REGION          194..205
FT                   /note="Interaction with histones"
FT                   /evidence="ECO:0000269|PubMed:27225933,
FT                   ECO:0000269|PubMed:39601790"
FT   REGION          288..293
FT                   /note="Interaction with KAP114"
FT                   /evidence="ECO:0000269|PubMed:27225933,
FT                   ECO:0000269|PubMed:39601790"
FT   REGION          364..417
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          366..417
FT                   /note="Interaction with ribosomal proteins eS6, eL39 and
FT                   eL42"
FT                   /evidence="ECO:0000269|PubMed:31062022"
FT   COMPBIAS        10..35
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        367..403
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        404..417
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         20
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17330950,
FT                   ECO:0007744|PubMed:18407956, ECO:0007744|PubMed:19779198"
FT   MOD_RES         24
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17330950,
FT                   ECO:0007744|PubMed:18407956, ECO:0007744|PubMed:19779198"
FT   MOD_RES         27
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17330950,
FT                   ECO:0007744|PubMed:18407956, ECO:0007744|PubMed:19779198"
FT   MOD_RES         53
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19779198"
FT   MOD_RES         69
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19779198"
FT   MOD_RES         76
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:15665377,
FT                   ECO:0007744|PubMed:17330950, ECO:0007744|PubMed:18407956,
FT                   ECO:0007744|PubMed:19779198"
FT   MOD_RES         82
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:18086883,
FT                   ECO:0007744|PubMed:19779198"
FT   MOD_RES         98
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:18086883"
FT   MOD_RES         104
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:18086883"
FT   MOD_RES         140
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:18086883,
FT                   ECO:0007744|PubMed:18407956"
FT   MOD_RES         159
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000269|PubMed:18086883"
FT   MOD_RES         177
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000269|PubMed:18086883,
FT                   ECO:0007744|PubMed:17330950, ECO:0007744|PubMed:18407956,
FT                   ECO:0007744|PubMed:19779198"
FT   MOD_RES         397
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000269|PubMed:18086883"
FT   CROSSLNK        50
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0007744|PubMed:22106047"
FT   MUTAGEN         99
FT                   /note="L->S: Predominantly cytoplasmic; when associated
FT                   with A-159, A-177 and S-397."
FT                   /evidence="ECO:0000269|PubMed:18086883"
FT   MUTAGEN         159
FT                   /note="S->A: Significant reduction in phosphorylation; when
FT                   associated with A-397. Complete inhibition of
FT                   phosphorylation; when associated with A-177 and A-397.
FT                   Leads to a prolonged S phase and a shortened passage
FT                   through G1; when associated with A-177 and A-397.
FT                   Predominantly cytoplasmic; when associated with S-99, A-177
FT                   and A-397."
FT                   /evidence="ECO:0000269|PubMed:18086883"
FT   MUTAGEN         159
FT                   /note="S->D: Leads to a prolonged S phase and a shortened
FT                   passage through G1; when associated with A-177 and A-397."
FT                   /evidence="ECO:0000269|PubMed:18086883"
FT   MUTAGEN         177
FT                   /note="S->A: Significant reduction in phosphorylation; when
FT                   associated with A-397. Complete inhibition of
FT                   phosphorylation; when associated with A-159 and A-397.
FT                   Leads to a prolonged S phase and a shortened passage
FT                   through G1; when associated with A-159 and A-397.
FT                   Predominantly cytoplasmic; when associated with S-99, A-159
FT                   and A-397."
FT                   /evidence="ECO:0000269|PubMed:18086883"
FT   MUTAGEN         177
FT                   /note="S->D: Leads to a prolonged S phase and a shortened
FT                   passage through G1; when associated with A-159 and A-397."
FT                   /evidence="ECO:0000269|PubMed:18086883"
FT   MUTAGEN         288..292
FT                   /note="EMRKQ->AMAKA: Abolishes the interaction with
FT                   KAP114."
FT                   /evidence="ECO:0000269|PubMed:39601790"
FT   MUTAGEN         290..305
FT                   /note="RKQRNKTTKQVRTIEK->PKQRNKTTKQVPPIEP: Disrupts
FT                   oligomerization of NAP1 dimers."
FT                   /evidence="ECO:0000269|PubMed:18068721"
FT   MUTAGEN         290
FT                   /note="R->P: Disrupts oligomerization of NAP1 dimers."
FT                   /evidence="ECO:0000269|PubMed:18068721"
FT   MUTAGEN         305
FT                   /note="K->P: Disrupts oligomerization of NAP1 dimers."
FT                   /evidence="ECO:0000269|PubMed:18068721"
FT   MUTAGEN         397
FT                   /note="S->A: Significant reduction in phosphorylation; when
FT                   associated with either A-159 or A-177. Complete inhibition
FT                   of phosphorylation; when associated with A-159 and A-177.
FT                   Leads to a prolonged S phase and a shortened passage
FT                   through G1; when associated with A-159 and A-177.
FT                   Predominantly cytoplasmic; when associated with S-99; A-159
FT                   and A-177."
FT                   /evidence="ECO:0000269|PubMed:18086883"
FT   MUTAGEN         397
FT                   /note="S->D: Leads to a prolonged S phase and a shortened
FT                   passage through G1; when associated with A-159 and A-177."
FT                   /evidence="ECO:0000269|PubMed:18086883"
FT   CONFLICT        2
FT                   /note="S -> T (in Ref. 1; AAA34811)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        103..104
FT                   /note="QS -> LC (in Ref. 1; AAA34811)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        137..138
FT                   /note="RI -> TM (in Ref. 1; AAA34811)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        384
FT                   /note="E -> D (in Ref. 1; AAA34811)"
FT                   /evidence="ECO:0000305"
FT   TURN            73..75
FT                   /evidence="ECO:0007829|PDB:2AYU"
FT   HELIX           84..87
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   HELIX           90..139
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   STRAND          141..143
FT                   /evidence="ECO:0007829|PDB:2AYU"
FT   HELIX           147..160
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   HELIX           163..165
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   HELIX           169..172
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   HELIX           176..179
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   HELIX           188..195
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   HELIX           199..202
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   HELIX           205..211
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   STRAND          214..222
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   STRAND          224..226
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   STRAND          228..235
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   TURN            237..239
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   STRAND          241..243
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   STRAND          246..254
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   HELIX           260..262
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   STRAND          266..271
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   TURN            279..281
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   STRAND          285..293
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   TURN            295..297
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   STRAND          300..308
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   HELIX           312..315
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   HELIX           325..327
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   HELIX           328..350
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   TURN            351..354
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   HELIX           357..361
FT                   /evidence="ECO:0007829|PDB:9B3I"
FT   TURN            362..364
FT                   /evidence="ECO:0007829|PDB:9B3I"
SQ   SEQUENCE   417 AA;  47885 MW;  C0F97FBA1B9EEA83 CRC64;
     MSDPIRTKPK SSMQIDNAPT PHNTPASVLN PSYLKNGNPV RAQAQEQDDK IGTINEEDIL
     ANQPLLLQSI QDRLGSLVGQ DSGYVGGLPK NVKEKLLSLK TLQSELFEVE KEFQVEMFEL
     ENKFLQKYKP IWEQRSRIIS GQEQPKPEQI AKGQEIVESL NETELLVDEE EKAQNDSEEE
     QVKGIPSFWL TALENLPIVC DTITDRDAEV LEYLQDIGLE YLTDGRPGFK LLFRFDSSAN
     PFFTNDILCK TYFYQKELGY SGDFIYDHAE GCEISWKDNA HNVTVDLEMR KQRNKTTKQV
     RTIEKITPIE SFFNFFDPPK IQNEDQDEEL EEDLEERLAL DYSIGEQLKD KLIPRAVDWF
     TGAALEFEFE EDEEEADEDE DEEEDDDHGL EDDDGESAEE QDDFAGRPEQ APECKQS
//
